Compare · CELZ vs SPGI
CELZ vs SPGI
Side-by-side comparison of Creative Medical Technology Holdings Inc. (CELZ) and S&P Global Inc. (SPGI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CELZ and SPGI operate in Finance: Consumer Services (Finance), so they compete in similar markets.
- SPGI is the larger of the two at $125.23B, about 20169.1x CELZ ($6.2M).
- SPGI has been more active in the news (16 items in the past 4 weeks vs 2 for CELZ).
- SPGI has more recent analyst coverage (25 ratings vs 1 for CELZ).
Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem for the treatment of erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine for the treatment of chronic lower back pain; Amniostem for the treatment of strokes, radiation, toxicity, and glioma; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. was incorporated in 1998 and is based in Phoenix, Arizona.
S&P Global Inc.
S&P Global Inc., together with its subsidiaries, provides ratings, benchmarks, analytics, and data to the capital and commodity markets worldwide. The company operates through four segments: S&P Global Ratings (Ratings), S&P Global Market Intelligence (Market Intelligence), S&P Global Platts (Platts), and S&P Dow Jones Indices (Indices). The Ratings segment offers credit ratings, research, and analytics to investors, corporations, governments, municipalities, commercial and investment banks, insurance companies, asset managers, and other debt issuers. The Market Intelligence segment provides multi-asset-class data, research, and analytical capabilities that integrate cross-asset analytics and desktop services to investment managers, investment banks, private equity firms, insurance companies, commercial banks, corporations, professional services firms, government agencies, and regulators. The Platts segment offers essential price data, analytics, and industry insights for the commodity and energy markets. It serves producers, traders, and intermediaries within the energy, petrochemicals, metals, and agriculture markets. The Indices segment provides index that maintains various valuation and index benchmarks for investment advisors, wealth managers, and institutional investors. The company also offers analytics, artificial intelligence, machine learning, and data visualization systems to Wall Street's premier global banks and investment institutions, as well as the National Security community; subscription and custom reports on bank deposits, loans, fees, and other product data to the financial services industry; and insights on global supply chains. The company was formerly known as McGraw Hill Financial, Inc. and changed its name to S&P Global Inc. in April 2016. S&P Global Inc. was founded in 1860 and is headquartered in New York, New York.
Latest CELZ
- President & CEO Warbington Timothy was granted 1,000,000 shares (SEC Form 4)
- Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing
- Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning
- SEC Form 10-Q filed by Creative Medical Technology Holdings Inc.
- Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms
- SEC Form 424B3 filed by Creative Medical Technology Holdings Inc.
- SEC Form EFFECT filed by Creative Medical Technology Holdings Inc.
- SEC Form S-3 filed by Creative Medical Technology Holdings Inc.
Latest SPGI
- S&P Global brings Visible Alpha data to the S&P Global AI Data Portal
- Derivnex Launches Industry-First OTC Swap on Canton with DRW and Marex
- S&P Dow Jones Indices and Kaiko Enable First On-chain OTC Swap Referencing a Tokenized Benchmark, Executed by DRW and Marex on Derivnex
- S&P Global Appoints New Chief Legal Officer
- ChatIQ Leads S&P Global's Latest Capital IQ Pro Update with Expanded AI-Powered Research Capabilities
- Freshworks Set to Join S&P SmallCap 600
- SEC Form 4 filed by S&P Global Inc.
- S&P Global Ratings launches Vault Risk Assessment for digital asset markets
- Vylor Added to the S&P 500; Twilio Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
- Eaglebrook Launches Crypto Direct Indexing Platform; Featuring the S&P Cryptocurrency Top 10 Equal Weight Index